New Lipid-Lowering Drugs: The Potential for Further Reductions in Cardiovascular Events

TL;DRAbstract

The advent of effective pharmacologic therapies for cardiovascular disease has resulted in marked reductions in cardiovascular morbidity and mortality in industrialized nations. Statin drugs (HMG-CoA reductase inhibitors) have played a major part in this success. By reducing hepatocyte sterol synthesis, and thereby increasing hepatocyte uptake of LDL, statins cause a lowering of circulating LDL cholesterol levels and thus reduce the substrate for atherosclerotic plaque formation.

Chat with Paper

AI Agents for this Paper